Soteria Biotherapeutics is a San Francisco-based immuno-oncology company developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumors. Its T-LITETM platform provides small molecule-dependent activation of bispecific antibody therapies, enabling pulsatile activity, reduced side effects, and higher dosing. The company intends to use the proceeds from its Series A to advance the T-LITE technology and build a pipeline of T-LITE development candidates targeting well-validated cancer targets. Soteria was founded in 2018 with technology licensed from UC San Francisco. Leadership includes CEO Kristine Ball and co-founder/CSO Zachary Hill, and the board features executives and investors from Pionyr Immunotherapeutics, 5AM Ventures, M Ventures, Roche Venture Fund, Novartis Venture Fund and Emerson Collective. The company raised $42M in a Series A led by Roche Venture Fund and 5AM Ventures, with participation from M Ventures, Novartis Venture Fund and Alexandria Venture Investments.

Total raised

$42M

Funding rounds

1

Latest round

Series A

Latest activity

May 2021